Navigation Links
Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
Date:11/2/2009

CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced the appointment of J. Michael Sprafka, MPH, PhD, as Vice President, Kendle Consulting. Dr. Sprafka will provide leadership for and drive the development of integrated product development consulting services to help biopharmaceutical companies accelerate time to market and maximize the long-term commercial value of their products. His focus will be on delivery of best-in-class consulting services for customers in the areas of regulatory affairs and submissions, risk management, epidemiology, pharmacovigilance, signal detection and safety evaluations, among others. Dr. Sprafka has held senior leadership roles in the pharmaceutical and government sectors as well as academia and brings the executive level leadership and analytical expertise needed to meet increasing customer demands and heightened global regulatory requirements. He will be based out of Kendle's global headquarters in Cincinnati and will report to Melanie Bruno, PhD, MBA, Vice President, Regulatory, Site and Medical Affairs.

"I am delighted to welcome Michael to the Kendle team," said Dr. Bruno. "His extensive and diverse experience will significantly enhance our ability to deliver best-in-class regulatory consulting services and risk management capabilities to our customers across Phase I through IV clinical development and beyond. As our customers' products move through the product life cycle, Kendle's Consulting team can assist in conducting sophisticated analyses from ongoing data sources to gain a greater understanding of side effects and adverse events and best reflect the products' safety for the patient."

The addition of Dr. Sprafka strengthens Kendle Consulting, a growing area of the Company dedicated to worki
'/>"/>

SOURCE Kendle International Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
2. Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition
3. Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
4. Qforma Appoints Erin McLaughlin as Director, Field Operations
5. VitaminSpice Appoints Dr. Richard F. Seelig as Director
6. Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
9. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
10. EUCODIS Bioscience Appoints Bhupinder Hundle to Senior Vice President Marketing & Sales
11. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- MedSolutions ( www.medsolutions.com ), a leading provider ... new studies highlighting the dangers of excess radiation ... tests. ,, "When used properly, CT imaging ... Gregg Allen, M.D., chief medical officer of MedSolutions. ... that stricter quality control measures are necessary to ...
(Date:12/16/2009)... Ohio, Dec. 16 HDT Engineered Technologies ... generation technologies and a principal subcontractor for the ... led development of new anthropromorphic arm technology that ... prosthetic arm and hand, including a sense of ... Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics 2009 ...
(Date:12/16/2009)... 16 Ethicon, Inc., a Johnson & ... a worldwide leader in surgical care, and Acclarent, ... to designing, developing and commercializing devices that address ... today announced a definitive merger agreement whereby Ethicon ... approximately $785 million net of estimated cash on ...
Breaking Medicine Technology:MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 15025 1Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 15025 2Neogen Acquires Gen Probes BioKits Food Safety Business 6639 1Neogen Acquires Gen Probes BioKits Food Safety Business 6639 2BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 6637 1BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 6637 2BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 6637 3
... Mass., Aug. 14 StatSure,Diagnostic Systems, Inc. (OTC Bulletin ... patented, "barrel- test" format for the detection of,antibodies to ... completed,the trials needed for a CLIA waiver application and ... Food & Drug Administration (FDA) for,their review. The Company ...
... Efficacy of LBH589 in ... Myeloma, NORWALK, Conn., Aug. 14 The Multiple ... Phase II,study to determine the efficacy of LBH589 for ... LBH589 is an orally,administered deacetylase inhibitor developed by Novartis ...
Other Medicine Technology:CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 2CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 3Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 2Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 3
(Date:12/16/2009)... CHICAGO, Dec. 16 Allscripts (Nasdaq: ... its financial results for the three and six ... market opens on Monday, January 11, 2010. Allscripts ... to discuss the company,s earnings and other information ... morning. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, ...
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... to disease , , WEDNESDAY, Dec. 16 (HealthDay News) ... leprosy have been identified by scientists in Singapore ... than 10,000 DNA samples from leprosy patients and ... the important role that the innate immune response ... leprosy is not common, the discoveries have significant ...
(Date:12/16/2009)... and environmental concerns about the emerging nanotechnology industry, scientists ... of nanoparticles in municipal sewage treatment plants their ... in ACS, journal Environmental Science & Technology . ... and Hydrology and colleagues note that experts predict large ... than 1/1000th the width of a human hair ...
(Date:12/16/2009)... Episencial Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- Actively ... choice in all natural skin care for their children as ... young children featuring the beloved artwork of The Very Hungry ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Leprosy Genes Identified 2Health News:Behavior modification could ease concerns about nanoparticles 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5
... its continued commitment to providing high-quality information to ... the prestigious journal Advances in Therapy, to be ... enhances its services for clients in the pharmaceutical, ... in Therapy, to be published by Springer Healthcare ...
... Another Scientific ... ... Association, DENVER, Oct. 31 "The WCRF/AICR recommendations about,red meat and cancer are ... of red meat in a healthy,diet that far outweigh anything we,ve seen today. ...
... in October is partly seasonal * ... regions post no over the year gains in advertised ... ... NEW YORK, Oct. 31 In October there were 4,161,700,online advertised vacancies, ...
... have a strong tropism for hepatocytes; viral antigen also ... is common in Fulminant hepatic failure but rarely reported ... viral hepatitis over a three year period were involved. ... had acute pancreatitis and 17 had stretching of glissons ...
... Calif., Oct. 31 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... $2.1 million from Merz Pharmaceuticals GmbH (Merz) for ... for the treatment of,moderate-to- severe Alzheimer,s disease for ... 27% increase in NTI,s royalty payments compared to,the ...
... Mass., Oct. 31 Biopure Corporation,(Nasdaq: BPUR ) ... A,common stock will revert from BPURD to BPUR at ... Outstanding warrants that trade on the OTCBB,will revert to ... to BPURZ; and BPREL reverting to BPURL. Biopure ...
Other Medicine News:Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 3Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 4Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 5Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 6Health News:Is it pancreatitis in acute abdominal pain in acute viral hepatitis? 2Health News:Biopure's Stock Symbol Reverts to BPUR 2
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... Type 300 ,Oblique 45, ,Type 330 ... illumination by setting the illumination between ... be ideal for use in ophthalmology ... other conventional compact microscope can; an ...
... is exactly the same as the model SP-8800 with ... separate Pachy mode. This mode has its own fixation ... all directions. It allows you to select an area ... has built-in software to calculate averages of multiple readings ...
... MedCath is the largest and most experienced ... networks in the United States. Mobile laboratories ... a daily basis, from one hospital to ... geographic area. Each mobile laboratory is fully ...
Medicine Products: